… Dual antiplatelet therapy (DAPT) has demonstrated a reduction in recurrent ischemic events.
The newer antiplatelets … decision-making in deciding duration of dual antiplatelet therapy. …

… Finally, to investigate whether duration of exposure to dual antiplatelet therapy was related
… to difference in duration of dual antiplatelet therapy exposure between study groups. Each of …

… antiplatelet … therapeutic combinations to be tailored to an individual patient’s bleeding and
ischemic risk profile. In this review, we will summarize the history of dual antiplatelet therapy, …

… at high bleeding risk to discontinue dual antiplatelet therapy immediately (abbreviated
therapy) or to continue it for at least 2 additional months (standard therapy). The three ranked …

… We enrolled patients older than 18 years of age who were candidates for dual antiplatelet
therapy after treatment with FDA-approved drug-eluting or bare-metal stents. Details of the …

… Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World
Clinical Practice] and RESET [REal Safety and Efficacy of 3-month dual antiplatelet Therapy …

… Over the past 4 decades, antiplatelet therapy after percutaneous coronary intervention (PCI)
has become an essential medication in everyday clinical practice. Dual antiplatelet therapy (…

… In addition, we did not identify significant beneficial effects of such dual antiplatelet therapy
… detect any significant difference between the effects of dual vs mono-antiplatelet therapies. …

… This study sought to assess the benefits and risks of 30 versus 12 months of dual antiplatelet
therapy among patients undergoing coronary stent implantation with and without MI. …

… 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed
in collaboration with EACTS: the Task Force for Dual Antiplatelet Therapy in Coronary …